Meiji will buy $50 million of unregistered Arcturus securities at $20.27 a share, according to the securities purchase agreement. The shares will represent 7.9% of Arcturus’s outstanding stock after the transaction. Arcturus shares are up 27% over the past 12 months.
The companies also signed an exclusive license agreement covering the application of Arcturus’ ARCT-154 technology in an undisclosed therapeutic area. Separately, a memorandum of understanding sets out principal terms for a potential collaboration and license agreement on pandemic preparedness and response in Japan using Arcturus’ platform.





Comments (0)
No comments yet. Be the first!